Please login to the form below

Not currently logged in
Email:
Password:

Trumenba

This page shows the latest Trumenba news and features for those working in and with pharma, biotech and healthcare.

Pfizer wins EU approval for MenB vaccine Trumenba

Pfizer wins EU approval for MenB vaccine Trumenba

Pfizer wins EU approval for MenB vaccine Trumenba. US pharma firm’s injection can now be given to patients aged 10 and above. ... Trumenba has been approved in Europe to prevent MenB in people aged 10 or above, more than four years after Bexsero first

Latest news

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    Keytruda and Opdivo backed for new uses in Europe. CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia. ... Trumenba has been approved for children aged 10 years or older, while Bexsero can be administered from two months.

  • Pfizer posts positive Trumenba vaccine data Pfizer posts positive Trumenba vaccine data

    Pfizer posts positive Trumenba vaccine data. Results from two new trials support FDA decision for accelerated approval. ... Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials.

  • US expands recommended use of meningitis B vaccines US expands recommended use of meningitis B vaccines

    US expands recommended use of meningitis B vaccines. Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba. ... But the panel - part of the US Centers for Disease Control and Prevention (CDC) - opted not to recommend routine vaccination

  • Pfizer teams up with snowboarder in meningitis campaign Pfizer teams up with snowboarder in meningitis campaign

    Pfizer's recent developments in meningitis include the FDA approval of its meningitis B vaccine Trumenba in October this year, ahead of a decision on Novartis' rival vaccine Bexsero.

  • Pfizer gets FDA nod for meningitis vaccine Trumenba Pfizer gets FDA nod for meningitis vaccine Trumenba

    Pfizer gets FDA nod for meningitis vaccine Trumenba. Ahead of Novartis’ rival drug Bexsero. ... Pfizer's Trumenba has become the first vaccine licensed in the US to protection meningitis B (menB), ahead of rival Bexsero from Novartis.

More from news
Approximately 5 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting (OAC) is the market access agency within OPEN Health. We are value communications experts and we specialise...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics